Genitourinary Cancers

Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in ccRCC.

Katy Beckermann, MD, PhD, discusses key findings from a PRO analysis of tivozanib/nivolumab vs tivozanib alone in ICI-pretreated RCC.

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.

Hedyeh Ebrahimi, MD, MPH, highlights the early activity of CBM588 plus cabozantinib/nivolumab for the treatment of patients with metastatic RCC.

Charles B. Nguyen, MD, provides insight into current challenges faced in the non–clear cell RCC landscape beyond the NCCN’s recent guideline updates.

Drs Park, Grivas, and Raychaudhuri discuss a trial of neoadjuvant aMVAC plus pembrolizumab in patients with non-urothelial muscle-invasive bladder cancer.

Pedro Barata, MD, provides insights on key updates in RCC, MIBC, and prostate cancer, as discussed during a State of the Science Summit™.

A phase 3 study will be initiated after completion of the first neoadjuvant phase 2 trial of platinum-based chemotherapy plus immunotherapy in UTUC.

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.

Some patients with metastatic kidney cancer achieving a good response to a combination therapy can safely stop or pause treatment after 2 years.

The European Commission approved belzutifan for select VHL-associated cancers and advanced clear cell renal cell carcinoma.

Adherence rates improved the longer patients with metastatic and nonmetastatic prostate cancer received relugolix for a high overall adherence rate.

Axel Merseburger, MD, PhD, discusses the real-world efficacy and safety of first-line avelumab plus axitinib in advanced renal cell carcinoma.

No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.

Nivolumab in combination with cabozantinib displayed a long-term PFS benefit in patients with treatment-naive advanced RCC.

CBM588 plus cabozantinib and nivolumab shows early efficacy in metastatic renal cell carcinoma.

The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.

Updated results further supported the feasibility of VEGFR TKI interruption and immunotherapy maintenance in advanced renal cell carcinoma.

Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.

An ER model analysis showed that 1.34 mg of tivozanib provided a greater decrease in tumor size and may be more tolerable than an 0.89-mg dose in RCC.

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Laurence Albigès, MD, PhD discusses final OS data and biomarker analyses with cabozantinib plus nivolumab and ipilimumab in intermediate- or poor-risk RCC.

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.